Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

NCT06768931 | Recruiting Phase 2

• 1 other identifier: SYSUCC-BC-PROBIOTIC
• Study Type: interventional
• Target: 192
• Locations: 1 country
• Sites: 5

Brief Summary

To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer

Conditions

Breast Cancer; Early Stage Breast Cancer; Triple Negative Breast Cancer (TNBC); Immunotherapy; Probiotic

Keywords

Triple negative breast cancer; Probiotics; Immunotherapy

Outcome Measures

Primary Outcomes (1)

• Pathological complete remission

  ypT0N0, ypTisN0 after surgery

  From enrollment to the end of treatment at 24 weeks

Secondary Outcomes (2)

• overall survival

  From enrollment to the end of treatment at 5 years

• Disease Free Survival

  From enrollment to the end of treatment at 5 years

Study Arms (2)

Experimental group

EXPERIMENTAL

Standard therapy (paclitaxel-carboplatin or docetaxel-carboplatin, and PD-1 antibody for 4 cycles followed by doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide, and PD-1 antibody for 4 cycle) combined with compound preparation Biolosion

Other: Biolosion (oral probiotic compound preparation)

Controlled group

NO INTERVENTION

Standard therapy, including paclitaxel-carboplatin or docetaxel-carboplatin, and PD-1 antibody for 4 cycles followed by doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide, and PD-1 antibody for 4 cycle.

Interventions

Biolosion (oral probiotic compound preparation) OTHER

Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.

Experimental group

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Women aged 1.18 years and above, diagnosed with triple-negative breast cancer (ER≤10%, PR≤10%, HER-2 negative) by pathology;
• Patients must have tumor specimens (formalin-fixed, paraffin-embedded, or fresh pre-treated tumor tissue) available for PD-L1 expression testing;
• Researchers assess indications for neoadjuvant chemotherapy, with staging from IIA to IIIC, based on imaging or pathological evaluation of cT1c, N1-3, or cT2\~cT4, cN0\~N3, and patients with no distant metastasis as evaluated by imaging;
• Patients must not have received chemotherapy or targeted therapy for advanced breast cancer;
• ECOG PS: 0-2;
• Expected survival of ≥12 weeks;
• Major organ function levels must meet the following criteria:
• \) Hematological examination standards must meet: ANC≥1.5×10\^9/L, PLT≥75×10\^9/L, Hb≥90g/L (no blood transfusions or blood products within 14 days, and no use of G-CSF or other hematopoietic growth factors for correction) 2) Biochemical examination must meet the following standards: TBIL\<1.5×ULN, ALT, AST\<2.5×ULN, for patients with liver metastasis, ALT, AST may be \<5×ULN, BUN and Cr≤1×ULN or endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days prior to enrollment, with a negative result, and must be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug.
• \. Participants voluntarily join this study, demonstrate good compliance, and cooperate with follow-up.

You may not qualify if:

• There is a clear distant transfer;
• A history of autoimmune diseases;
• Acute or chronic active hepatitis B (defined as positive hepatitis B surface antigen and/or hepatitis B core antibody, with hepatitis B virus DNA copy number ≥1×10³ copies/ml or ≥200 IU/ml) or positive antibodies for acute or chronic active hepatitis C, with positive hepatitis C antibodies but negative RNA testing allowed for enrollment.
• Previous treatment with immune checkpoint inhibitors;
• Received systemic immunostimulants, systemic corticosteroids, or immunosuppressants within the last 4 weeks;
• Any severe underlying disease, comorbidities, and active infections, or patients with severe metabolic disorders;
• Currently receiving other antitumor treatments;
• Known comorbidities (e.g., chronic diarrhea, inflammatory bowel disease, etc.) that, in the investigator's assessment, would increase the risk associated with the administration of the study drug or interfere with the interpretation of study results.
• Currently using or planning to use probiotics, yogurt, or bacterial-enhanced foods during the treatment period.
• A history of epilepsy or seizure-inducing states;
• Pregnant or breastfeeding patients;
• Poor compliance or inability to undergo normal follow-up;
• Individuals allergic to the study drug;
• Diagnosis of other malignancies within the past 5 years, with the exception of: surgically removed non-melanoma skin cancer, adequately treated cervical carcinoma in situ, locally curative prostate cancer, surgically treated ductal carcinoma in situ, or malignancies diagnosed 2 years prior to randomization without evidence of disease and untreated for ≤2 years;
• The investigator's judgment on other conditions that may affect the conduct of the clinical study and the determination of study results.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (5)

Gansu Cancer Hospital

Lanzhou, Gansu, 730050, China

NOT YET RECRUITING

Dongguan People's Hospital

Dongguan, Guangdong, 523059, China

NOT YET RECRUITING

Sun yat sen university cancer center

Guangzhou, Guangdong, 510060, China

RECRUITING

Central Hospital of Guangdong Nongken

Zhanjiang, Guangdong, 524002, China

NOT YET RECRUITING

Zigong Fourth People's hospital

Zigong, Sichuan, 643000, China

NOT YET RECRUITING

MeSH Terms

Conditions

Breast Neoplasms; Triple Negative Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Meiting Chen, Doctor

CONTACT

020-87343368; chenmt@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Patients in experimental group will be treated with standard neoadjuvant chemotherapy, immunotherapy combined with Biolosion (oral probiotic compound preparation). Patients in controlled group will be treated with standard neoadjuvant chemotherapy and immunotherapy.

Study Record Dates

• First Submitted: January 6, 2025
• First Posted: January 10, 2025
• Study Start: April 1, 2026
• Primary Completion (Estimated): January 8, 2030
• Study Completion (Estimated): February 8, 2035
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

CN (5)